Top Banner Top Banner

1. American Cancer Society. Ovarian Cancer, 2011.

2. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.

3. Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000;83(2):196-203.

4. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-5728.

5. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007;25:5165-5171.

6. Penson rt, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010;28:154-159.

7. Tillmanns TD, Lowe MP, Schwartzberg LS, et al. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010;28(7s):Abstr 5009.

8. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2010;28(18s):Abstr LBA 1.

9. Perren T, Swart AM, Pfisterer J, et al. ICON7: A phase III randomized gynecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevecizumab versus chemotherapy alone in women with new diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann of Oncol 2010;21(Suppl 8):LBA4.

10. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebo controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum sensitive epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 29;2011(suppl; abstr LBA5007).

11. Hainsworth JD, Numnum TM, Rao GG. A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. J Clin Oncol 2010;28(15s):Abstr TPS257.

12. NCT00436215. Sorafenib and bevacizumab to treat ovarian, fallopian and peritoneal cancer. Accessed January 18, 2011.

13. NCT00532194. An RCT of concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer (ICON6). Accessed January 19, 2011.

14. NCT00866697. Efficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer. Accessed January 19, 2011.

15. Ledermann JA, Rustin GJ, Hackshaw A, et al. A randomized phase II placebo controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer. J Clin Oncol 2009;27(15s):Abstr 5501.

16. NCT01015118. BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first-line treatment of ovarian cancer. Accessed January 19, 2011.

17. Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL 184) in advanced ovarian cancer patients: results from a phase II randomized discontinuation trial. J Clin Oncol 29;2011(suppl; abstr 5008).

18. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-3565.

19. Karlan BY, Oza AM, Hansen VL, et al. Randomized, double-blind, placebo controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2010;28(15s):Abstr 5000.

20. NCT01204749. TRINOVA-1: A study of AMG 386 or placebo in combination with weekly paclitaxel chemotherapy as treatment for ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. Accessed January 19, 2011.

21. Richardson DL, Backes FJ, Hurt JD, et al. What factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 2010;118:47-51.

22. Tanyi JL, McCann G, Hagemann AR, et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 2010; in press.

23. System ENABLEā„¢.


Last updated March 1, 2012